miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Cancer
Huvudupphovsmän: van Jaarsveld, Marijn T. M., van Kuijk, Patricia F., Boersma, Antonius W. M., Helleman, Jozien, van IJcken, Wilfred F., Mathijssen, Ron H. J., Pothof, Joris, Berns, Els M. J. J., Verweij, Jaap, Wiemer, Erik A. C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2015
Ämnen:
Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://ncbi.nlm.nih.gov/pubmed/26576679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-015-0464-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk